The use of a combination of photodynamic therapy and an anti-VEGF agent in thetreatment of conditions characterizedby unwanted choroidal neovasculature is described. These conditions includewet age-related macular degeneration Preferredanti-VEGF agents are antibodies such as bevacizumab or ranibizumabPhotosensitizers may be selected from green porphyrinssuch as BPD-MA (verteporfin) and the photodynamic activation of thephotosensitizer may be accomplished using a reducedfluence rate. The use may further comprises an anti-inflammatory agent such adexamethasone.